Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126372251 | 12637225 | 1 | I | 201603 | 20160725 | 20160809 | 20160809 | PER | US-AMGEN-USASP2016097573 | AMGEN | 45.00 | YR | A | F | Y | 104.31000 | KG | 20160809 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126372251 | 12637225 | 1 | PS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 50 MG, QWK | Y | Y | 103795 | 50 | MG | UNKNOWN FORMULATION | /wk | ||||
| 126372251 | 12637225 | 2 | SS | AZO | PHENAZOPYRIDINE HYDROCHLORIDE | 1 | Unknown | UNK | 0 | ||||||||||
| 126372251 | 12637225 | 3 | SS | AZO | PHENAZOPYRIDINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126372251 | 12637225 | 4 | SS | MELOXICAM. | MELOXICAM | 1 | Unknown | UNK | 0 | ||||||||||
| 126372251 | 12637225 | 5 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Unknown | UNK, BID | 0 | BID | |||||||||
| 126372251 | 12637225 | 6 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | 0 | ||||||||||||
| 126372251 | 12637225 | 7 | C | AMITRIPTYLINE | AMITRIPTYLINE | 1 | 0 | ||||||||||||
| 126372251 | 12637225 | 8 | C | RIZATRIPTAN. | RIZATRIPTAN | 1 | 0 | ||||||||||||
| 126372251 | 12637225 | 9 | C | DILTIAZEM. | DILTIAZEM | 1 | 0 | ||||||||||||
| 126372251 | 12637225 | 10 | C | CLONAZEPAM. | CLONAZEPAM | 1 | 0 | ||||||||||||
| 126372251 | 12637225 | 11 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126372251 | 12637225 | 12 | C | ETODOLAC. | ETODOLAC | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126372251 | 12637225 | 1 | Rheumatoid arthritis |
| 126372251 | 12637225 | 2 | Urinary tract infection |
| 126372251 | 12637225 | 3 | Pain |
| 126372251 | 12637225 | 4 | Product used for unknown indication |
| 126372251 | 12637225 | 5 | Urinary tract infection |
| 126372251 | 12637225 | 6 | Pain |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126372251 | 12637225 | Abdominal discomfort | |
| 126372251 | 12637225 | Diarrhoea | Diarrhoea |
| 126372251 | 12637225 | Drug effect decreased | |
| 126372251 | 12637225 | Drug hypersensitivity | |
| 126372251 | 12637225 | Hepatic enzyme increased | |
| 126372251 | 12637225 | Mobility decreased | |
| 126372251 | 12637225 | Nausea | Nausea |
| 126372251 | 12637225 | Pain | |
| 126372251 | 12637225 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126372251 | 12637225 | 1 | 201603 | 20160723 | 0 | |
| 126372251 | 12637225 | 2 | 201606 | 201606 | 0 | |
| 126372251 | 12637225 | 4 | 2016 | 0 | ||
| 126372251 | 12637225 | 5 | 201606 | 201606 | 0 |